whatshot

IOVA   $8.54  3.64% Market Closed After Close 8.61 0.82%

Iovance Biotherapeutics Inc
show_chart Advanced Chart of IOVA
Last Events:

2024-02-19 The hottest instrument.

2024-02-18 The hottest instrument.

2024-02-17 The hottest instrument.

2023-08-09 Signal in Stochastic changed from bullish to bearish. The stochastic indicator is in the lower part of the neutral territory and it heading south. These factors indicate that negative dynamics is recovering. Last signal: down-crossing the middle level.

2023-08-09 Signal in MACD changed from bearish weakening to bearish recovery. Oscillator MACD is in the negative territory it's lower than the signal line and falls. These factors mean that negative mood prevails. Last signal: main and signal line crossing.

2023-08-09 Signal in RSI changed from bearish weakening to bearish recovery. RSI indicator is in the lower part of the neutral territory and it heading south. These factors indicate that negative dynamics is recovering. Last signal: exit from the overbought zone.

2023-08-09 Trend Power changed from slow to almost flat.

2023-08-06 Trend Power changed from almost flat to slow.

Current temperature: 6.62
ST: 0, Cor:

Analyst Recommendations:
Number of estimates 13
Target Price Mean 23.77
Mean unverified/preliminary 23.77 / 23.77
Target Price Low / High 10.00 / 34.00
Median / STD DEV 24.00 / 6.22
Tech Forecasts:
More signals
  < 1M 1-3M > 3M
total None ActivelyBuy ActivelyBuy
rsi Sell None None
macd None None None
stoch None None None
ma20 Sell ActivelyBuy ActivelyBuy
ma50 None None None
ma100 Buy Buy None
Candlestick PatternNov. 19, 2024 Doji - is formed when the open and the close are the same or very close. The body of candle is small. The length of the shadows are not important. The appearance of a Doji should alert the investor of major indecision.
ISIN US4622601007
ceo Dr. Frederick G. Vogt Esq., J.D., Ph.D.
Website https://www.iovance.com
Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.